Menu

Close

Sign InSign Out

Order

See all

Order

Co-pay cards & patient savings offers

Materials

Samples*

Hospital products

Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​

Patient Assistance

Find available assistance programs

Go to Patient Assistance

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Explore content

Explore more content

Explore content

Events

Videos

Materials

Contact

See all contact

Contact

Pfizer corporate

Ask a question

Menu

Close

Home

About

About

Storage and handling

Vial sizes and NDC numbers

Purchasing Information

Biochemical composition and manufacturing

Dosing & Infusion Rates

Dosing & Infusion Rates

CIDP

Dosing and administration

Infusion rate chart

PI

Dosing and administration

Infusion rate chart

cITP

Dosing and administration

Infusion rate chart

Efficacy

Efficacy

CIDP

Study design

INCAT responder rates

Supporting efficacy endpoints

Dose adjustments

PI

Study designs

Primary endpoint, secondary endpoints, and safety assessments

cITP

Study design, primary endpoint, and secondary endpoints

Safety & Tolerability

Safety & Tolerability

CIDP

Adverse reactions

PI

Adverse reactions

cITP

Adverse reactions

Support

Support

Materials

Videos

Pfizer IGuideTM

Pfizer PANZYGA Co-Pay Program for patients

Frequently asked questions

Request a representative

Dosing & Infusion Rates

PI

PI
​​​​​​​dosing and administration
 
PI
infusion rate chart
 

The PANZYGA infusion rate chart below will help you calculate the appropriate infusion rate for a patient with PI

  • 300 mg/kg to 600 mg/kg body weight (3-6 mL/kg) administered every 3 to 4 weeks1
  • The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15-30 minutes, as tolerated, to a maximum of 14 mg/kg/min (0.14 mL/kg/min)1

Card Header

Header

This text is for block level content. P tags can go in here too

  • The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15-30 minutes, as tolerated, to the maximum infusion rate of 8 mg/kg/min (0.08 mL/kg/min)1 

Download the PANZYGA PI Infusion Rate Chart

** This is an optional area where footnotes can live.

References
  1. PANZYGA [prescribing information]. Paramus, NJ: Octapharma USA Inc.; 2021.

PI efficacy data for PANZYGA

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Review now

** This is an optional area where footnotes can live.

PI safety and tolerability data for PANZYGA

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Review data

** This is an optional area where footnotes can live.

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]

Contraindications

PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.

Warnings and Precautions

Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.

Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA.

Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion.

Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.

Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).

Monitor blood pressure prior to, during, and following PANZYGA infusion.

Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.

PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.

Adverse Reactions

PI – The most common adverse reactions (≥5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain.

cITP in adults – The most common adverse reactions (≥5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia.

CIDP in adults – The most common adverse reactions reported in greater than 5% of subjects were: headache, fever, dermatitis, and blood pressure increase.
​​​​​​​
The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

PANZYGA® is a registered trademark of Octapharma AG.

Please click here for Full Prescribing Information, including BOXED WARNING.

PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.

INDICATION AND USAGE

PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.

    Please see full Prescribing Information, including BOXED WARNING.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.

    Would you like to sign in now?